Search

everythinglearnresearchcommunity

for

Search:↓

First patient dosed with Pyrilutamide (Kintor) Phase III for hair loss treatment. Pyrilutamide differs from approved treatments as it competes with DHT to bind hair follicles, potentially reducing side effects.

Inconsistent minoxidil use led to hair loss, prompting a plan to resume consistent application with derma stamping, red light therapy, and DHT blockers like clascoterone or RU58841. The user avoids finasteride and dutasteride due to past side effects.

The conversation is about using pyrilutamide and RU58841 as topical solutions to prevent hair loss. Pyrilutamide is considered safer but less potent than RU58841, which some users find effective despite potential side effects like heart palpitations.

The conversation is about finding affordable topical anti-androgens for hair loss. The user is currently using finasteride, dutasteride, and oral minoxidil, and is advised that additional topical treatments may not be necessary.

Clascoterone phase 3 results show promising improvements in hair count, but concerns about high costs and lack of detailed data remain. Users compare it to existing treatments like Minoxidil and Finasteride, expressing skepticism about its accessibility and effectiveness.

Minoxidil and Nizoral alone are unlikely to stop hair loss effectively, as they do not address the root cause, which is often DHT. Many users suggest incorporating a 5AR inhibitor like finasteride or dutasteride for better results, despite concerns about potential side effects.

The user reported significant hair regrowth and stopped hair loss after using Pyrilutamide and Minoxidil for four months. They found Pyrilutamide effective in blocking DHT locally without side effects, preferring a gray market version over Koshine's product.

After six months of using a 0.50mm derma roller, 5% minoxidil, and a 5000 mcg biotin supplement, the user saw hair improvement. They are considering alternatives to finasteride due to concerns about side effects.

A 39-year-old male is experiencing hair regrowth after three months using 1mg oral finasteride daily, 5% topical minoxidil twice daily, dermastamping twice a month, and 2% ketoconazole shampoo weekly. He shares progress photos and receives encouragement and advice from others, noting some improvement and considering additional treatments but is limited by budget.

Breezula's phase 3 results are expected in July or August, with commercialization possibly in two years. There are concerns about delays and effectiveness, and the cost may be high.

The user is considering switching from finasteride to dutasteride for hair loss. They are unsure if GT20029 can regrow hair, particularly on the temples. Another user mentions that regrowth on finasteride can take up to 2 years.

PP405 is a new topical treatment for hair loss, showing promise in trials but still requires finasteride for maintenance. There is skepticism about its effectiveness and safety, with concerns about needing finasteride to maintain results.

A 24-year-old experienced significant hair regrowth over 8 months using oral finasteride, oral and topical minoxidil, dutasteride, microneedling, and ketoconazole shampoo. They are satisfied with the results and may consider a hair transplant after one year.

A 35-year-old is considering Breezula, Pyrilutamide, or topical finasteride/dutasteride to protect against hair loss while on testosterone replacement therapy (TRT). They currently use finasteride, oral minoxidil, and dutasteride but experienced increased hair shedding with TRT.

Clascoterone 5% solution (Breezula) is a promising alternative for androgenetic alopecia, showing continued hair growth with consistent use and no significant side effects. It may be suitable for those who cannot tolerate finasteride or dutasteride, especially when trying to conceive.

Hair loss treatments like Breezula and PP405 are delayed, with approvals taking years, while existing treatments like minoxidil and finasteride remain popular. New treatments like Clascoterone and Veradermics are in trials, but high costs and lengthy approval processes slow their release.

The user is using minoxidil, topical finasteride, Nizoral shampoo, and a dermaroller for hair regrowth but is experiencing changes in sexual function. They are concerned about whether these changes are due to the treatment and are seeking advice on continuing hair growth without affecting sexuality.

The conversation discusses hair loss treatments, with the main focus on using Fluridil and considering switching to Pyrilutamide. Other treatments mentioned include minoxidil, topical finasteride, nizoral shampoo, and saw palmetto supplements, with advice to stick with Fluridil for at least six months before considering alternatives.

Breezula shows promising hair growth results, with up to 539% increase in hair count compared to placebo, and regulatory submissions are planned in the US and EU. Users are cautiously optimistic, noting the potential for Breezula to replace finasteride by targeting DHT without systemic effects.

Hair loss treatments like finasteride, minoxidil, and dutasteride are popular but often lead to side effects and mixed results. The discussion stresses consulting medical professionals and being wary of unproven treatments in the hair loss industry.

Topical finasteride and minoxidil are not effective for the user, who is considering switching to oral treatments like finasteride or dutasteride. Many suggest oral medications are more effective, and some recommend additional treatments like microneedling and other topical solutions.

Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgen receptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.

A user shared their experience with hair loss treatments, using minoxidil, pyrilutamide, alfatrodial, and nizoral to improve hair density and thickness. They reported positive results without side effects and emphasized the importance of consistency with topical treatments.

A 21-year-old is experiencing severe hair loss despite using finasteride and minoxidil, and plans to try dutasteride. Others share similar struggles and suggest various treatments like RU58841, spironolactone, and hair systems, while emphasizing the emotional impact of hair loss.

GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.

Red light therapy for hair loss is controversial, with mixed results reported. Its effectiveness may depend on device quality and proper wavelength, and it is often used with minoxidil and finasteride.

Switching from finasteride to dutasteride can improve hair regrowth with fewer side effects for some users. Concerns about shedding, lack of improvement, and the long-term safety of oral minoxidil remain.

Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.

A user shared their 6-month update on hair loss treatment, using daily Dutasteride, oral and topical Minoxidil, Ketoconazole shampoo, topical Finasteride, dermastamping, and PRP treatments. They reported improved hair quality but no significant regrowth or density increase, and plan to continue the regimen for another year before considering a hair transplant.

Breezula offers modest hair growth similar to finasteride and is expected to be available by late 2026. It is a safe alternative without hormonal side effects and works well with minoxidil.